Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose DS-8500a PK and safety in Japanese subjects with hepatic or renal impairment
jRCT2080223081Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of firuglipel in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Pharmacokinetics of DS-8500a and Safety and tolerability of DS-8500a.
02
Drugs
firuglipel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223081.